Cardio-oncology has developed as a new field due to the proliferation of novel cancer therapies that not only have improved outcomes for some types of cancer, but also may lead to various cardiovascular toxicities.1 Older therapies, such as anthracyclines, are associated with cardiomyopathy as a result of myocyte death at the time of treatment, followed by cardiac remodeling in the years following completion of therapy, and eventually lead to heart failure (HF). In 2019, data are limited on the prevention and treatment of cancer treatment–associated cardiomyopathy, with most interventions extrapolated from general HF clinical trials, which often exclude patients with cancer. Clinical studies are needed that focus on patients with cancer and cancer survivors with cardiovascular issues.
Meijers WC, Moslehi JJ. Need for Multidisciplinary Research and Data-Driven Guidelines for the Cardiovascular Care of Patients With Cancer. JAMA. 2019;322(18):1775–1776. doi:10.1001/jama.2019.17415
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: